Chest Journal Podcasts

Manu Jain, MD, and Steven Shepherd, MPH and a long-time cystic fibrosis patient, join D. Kyle Hogarth, MD, FCCP, for this discussion of the debate on the policy of allowing only one adult patient with cystic fibrosis to attend any indoor events. Dr. Jain argues that risks are great enough to make this policy a good one. Mr. Shepherd argues that the concept is based on outdated ideas, the risks are very small, and that adults should be able to make their own choices on the risks they want to take.

Simon J. Finney, PhD, MBChB, editiorialist Arthur P. Wheeler, MD, FCCP, and CHEST Podcast Editor, D. Kyle Hogarth, MD, FCCP, discuss an article by Dr. Finney and others that reviews their research into modifying the traditional definition of the systemic inflammatory response syndrome (SIRS) following cardiac surgery. They found that they could improve the predictive value of SIRS criteria when the definition was adjusted to meeting three or more criteria or, most especially, fulfilling two or more of the criteria for at least six consecutive hours.

This month, CHEST Podcast Editor D. Kyle Hogarth, MD, FCCP, presents a special topic podcast on the recent vote of the Centers for Medicare and Medicaid Services (CMS) national coverage determination panel that there is not enough evidence to warrant Medicare coverage of low-dose CT screening for lung cancer. He is joined in conversation by Frank C. Detterbeck, MD, FCCP (Yale University), Scott Manaker, MD, PhD, FCCP (University of Pennyslvania), and David F. Yankelevitz, MD (Mount Sinai Hospital). They address some of the factors that went into the decision. Drs. Detterbeck, Manaker, and Yankelevitz also provide their interpretations of the important National Lung Screening Trial (NLST) and the results of studies from the International Early Lung Cancer Action Program (I-ELCAP), a multicenter clinical study in which patients were screened with CT using a common protocol.

Christopher J. Ryerson, MD, and editorialist Athol U. Wells, MD, join CHEST Podcast Editor, D. Kyle Hogarth, MD, FCCP, to discuss the study by Dr. Ryerson and others extending the use of the GAP risk prediction model (which is based on gender, age, and lung physiology) for chronic interstitial lung disease (ILD) to patients with idiopathic pulmonary fibrosis (IPF) and non-IPF ILDs. They consider the utilty of applying a single clinical prediction model for accurate mortality estimation across multiple ILD subtypes and discuss the possibilities of staging.